Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers

BACKGROUND: Dyslipidemia and type 2 diabetes are two of the most significant risk factors for the development of cardiovascular disease. Measurement of lipoprotein subclasses provides important information about derangements in lipid metabolism and helps refine cardiovascular risk assessment. Exenat...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Chiquette, Elaine, Toth, Peter P, Ramirez, Gilbert, Cobble, Michael, Chilton, Robert
Materialtyp: Artigo
Språk:Inglês
Publicerad: Dove Medical Press 2012
Ämnen:
Original Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3500143/
https://ncbi.nlm.nih.gov/pubmed/23166441
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/VHRM.S37969
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk